Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tri-Parametric Assessment of α-Galactosidase A Activity, lysoGb3 and X-Inactivation Aids Genotype-Phenotype Categorization of Fabry Disease Female Patients.

Journal of inherited metabolic disease·2026
Same author

Intersaphenous veins in a population with a high prevalence of chronic venous insufficiency.

Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft·2026
Same author

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.

Orphanet journal of rare diseases·2026
Same author

Evaluation of the severity of right-to-left shunt in patent foramen ovale patients after systemic embolism (MEASURE-PFO study).

Kardiologia polska·2026
Same author

Expert opinion on facilitating intrafamily communication in rare diseases-Lessons from Fabry disease.

Genetics in medicine open·2026
Same author

A non-coding signature in SHROOM3 is associated with kidney disease progression in Fabry disease.

Molecular genetics and metabolism·2026

Related Experiment Video

Updated: Jun 18, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

A validated disease severity scoring system for Fabry disease.

Edward H Giannini1, Atul B Mehta, Max J Hilz

  • 1Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45220, USA. edward.giannini@cchmc.org

Molecular Genetics and Metabolism
|December 3, 2009
PubMed
Summary

A new Fabry disease severity scoring system (DS3) was developed to reliably assess Fabry disease burden and progression. This validated tool shows excellent correlation with expert clinical assessments, aiding in patient monitoring and research.

More Related Videos

Computerized Adaptive Testing System of Functional Assessment of Stroke
05:21

Computerized Adaptive Testing System of Functional Assessment of Stroke

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 18, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Computerized Adaptive Testing System of Functional Assessment of Stroke
05:21

Computerized Adaptive Testing System of Functional Assessment of Stroke

Published on: January 7, 2019

Area of Science:

  • Genetics and rare diseases
  • Lysosomal storage disorders
  • Clinical assessment tools

Background:

  • Fabry disease is a progressive, life-threatening lysosomal storage disorder.
  • A validated and feasible scoring system is crucial for monitoring disease progression and treatment response.
  • Current methods lack a standardized tool for quantifying Fabry disease severity.

Purpose of the Study:

  • To develop and validate a new Fabry disease severity scoring system (DS3).
  • To establish a reliable instrument for quantifying disease burden and monitoring progression.
  • To facilitate comparisons of disease status in clinical studies.

Main Methods:

  • Expert consensus formation and statistical techniques were employed.
  • Domains and items were refined, and scoring was optimized for correlation with clinical global impression of severity (CGI-S).
  • Content validity, feasibility, inter-rater reliability, and criterion validity were assessed.

Main Results:

  • The Fabry DS3 model includes 5 domains: Peripheral Nervous System, Renal, Cardiac, Central Nervous System, and Patient-Reported.
  • High Content Validity Index (0.96) and Feasibility Index (0.97) were achieved.
  • Excellent criterion and construct validity (R²=0.89 with CGI-S) and high inter-rater reliability were demonstrated.

Conclusions:

  • The Fabry DS3 is a feasible and reliable instrument for assessing Fabry disease severity and progression.
  • The DS3 facilitates objective disease monitoring and comparison across patient cohorts.
  • This scoring system supports clinical management and research in Fabry disease.